France approves AstraZeneca for patients over the age of 65

France approves AstraZeneca for patients over the age of 65

France approves AstraZeneca for patients over the age of 65

France is to expand its use of the Oxford/AstraZeneca Covid-19 vaccine after additional clinical data proved its efficacy among people aged over 65, reversing the position Paris took a month ago. The French government partly reversed on Monday its decision not to use the AstraZeneca COVID-19 vaccine for the elderly.

“People affected by co-morbidities can be vaccinated with AstraZeneca, including those aged between 65 and 74,” the health minister said. Last month France approved use of the vaccine for under-65s only, citing lack of data for older people.

The Oxford-AstraZeneca vaccine is widely used across the UK, but several EU countries are still limiting it to the under-65s, including Germany. The government also endorsed a recommendation from the country’s High Authority for Health (HAS) to administer a single dose of the vaccine to people who have previously contracted the deadly virus, becoming the first country to do so.

France’s change of heart coincides with a real-world study conducted in Britain that found the COVID-19 vaccines developed by Pfizer-BioNTech and Oxford University-AstraZeneca are highly effective in protecting elderly people from the disease after receiving just one shot. 

Paid Content